Over the past decade, chimeric antigen receptor T cells have emerged as a breakthrough cancer therapy in selected hematologic malignancies. Translating the success of this therapy to solid tumors is challenging. In this issue, we discuss strategies potentially useful to increase the chimeric antigen receptor T-cell efficacy in this clinical indication.
GD2 Target Antigen and CAR T Cells: Does It Take More Than Two to Tango? / Locatelli, Franco; Quintarelli, Concetta. - In: CLINICAL CANCER RESEARCH. - ISSN 1557-3265. - 30:16(2024), pp. 3361-3363. [10.1158/1078-0432.CCR-24-0486]
GD2 Target Antigen and CAR T Cells: Does It Take More Than Two to Tango?
Locatelli, Franco
;Quintarelli, ConcettaUltimo
2024
Abstract
Over the past decade, chimeric antigen receptor T cells have emerged as a breakthrough cancer therapy in selected hematologic malignancies. Translating the success of this therapy to solid tumors is challenging. In this issue, we discuss strategies potentially useful to increase the chimeric antigen receptor T-cell efficacy in this clinical indication.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
